Skip to main content
Terug
Watch Compare

Neurogene Inc.

Datakwaliteit: 100%
NGNE
Nasdaq Manufacturing Chemicals
€ 20,99
▼ € 0,62 (-2,87%)
Marktkapitalisatie: 326,90 M
Prijs
€ 20,99
Marktkapitalisatie
326,90 M
Dagbereik
€ 20,76 — € 21,70
52-Weeksbereik
€ 8,05 — € 37,27
Volume
68.686
Openen € 21,59
50D / 200D Gem.
€ 19,77
6,19% above
50D / 200D Gem.
€ 21,29
1,41% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -78,36 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-100,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-33,54%
Boven sectorgemiddelde (-53,41%)
ROIC-29,42%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio18,39
Interest Coverage-20665,60

Waardering

PE (TTM)
-3,62
Onder sectorgemiddelde (-1,48)
P/B Ratio1,23
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -3,6 -1,5
P/B 1,2 1,6
ROE % -33,5 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
0,86% weight
MSGCX MSGCX
0,20% weight
MSGAX MSGAX
0,20% weight
MSGRX MSGRX
0,20% weight
MSGGX MSGGX
0,20% weight
MISGX MISGX
0,20% weight
IWV logo IWV iShares Russell 3000 ETF
0,00% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -100,00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -90,35 M
ROE -33,54% ROA -30,88%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -78,36 M
ROIC -29,42% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 18,39
Interest Coverage -20665,60 Asset Turnover 0,00
Working Capital 255,81 M Tangible Book Value 265,54 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,62 Forward P/E N/A
P/B Ratio 1,23 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -23,97%
Market Cap 326,90 M Enterprise Value 255,90 M
Per Share
EPS (Diluted TTM) -4,24 Revenue / Share 0,00
FCF / Share -5,03 OCF / Share -4,96
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 86,72%
SBC-Adj. FCF -91,65 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 925.000,0 — — —
Net Income -90,35 M -75,14 M -36,32 M -57,56 M -60,69 M
EPS (Diluted) -4,24 -4,28 2,93 -1,04 -1,10
Gross Profit — — — — —
Operating Income -103,33 M -82,61 M -55,58 M -59,10 M -60,70 M
EBITDA — — — — —
R&D Expenses 75,01 M 60,92 M 44,39 M 41,13 M —
SG&A Expenses — — — — —
D&A 3,04 M 3,20 M 3,26 M 1,56 M 1,31 M
Interest Expense 5.000,0 12.000,0 12.000,0 1,58 M —
Income Tax 0,0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 288,60 M 335,73 M 222,57 M 115,95 M 163,26 M
Total Liabilities 23,72 M 25,36 M 36,55 M 21,62 M 20,40 M
Shareholders' Equity 264,89 M 310,38 M 186,02 M 94,33 M 142,86 M
Total Debt — — — — —
Cash & Equivalents 103,85 M 136,59 M 148,21 M 37,89 M 142,47 M
Current Assets 271,77 M 315,92 M 200,35 M 99,13 M 143,99 M
Current Liabilities 16,41 M 15,16 M 22,97 M 11,06 M 8,64 M